Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561602 | 0.86 | KMT2A (0.47) | TSHRHSD17B10POLBRAB9ATHRB | |
| SCHEMBL12871180 | 0.75 | THRB (0.43) | TSHRHSD17B10POLBTHRBSMN1; SMN2 | |
| SCHEMBL19198662 | 0.75 | THRB (0.48) | TSHRPOLBRAB9ATHRBSMN1; SMN2 | |
| SCHEMBL6559314 | 0.74 | KMT2A (0.49) | TSHRPOLBTHRBSMN1; SMN2ALDH1A1 | |
| SCHEMBL12858430 | 0.73 | TSHR (0.58) | TSHRHSD17B10POLBRAB9ASMN1; SMN2 | |
| SCHEMBL12858044 | 0.73 | TSHR (0.68) | TSHRHSD17B10POLBRAB9ASMN1; SMN2 | |
| SCHEMBL12858017 | 0.73 | TSHR (0.58) | TSHRHSD17B10POLBRAB9ASMN1; SMN2 | |
| SCHEMBL6561558 | 0.71 | KMT2A (0.58) | TSHRTHRBALDH1A1PKMKMT2A | |
| SCHEMBL10830538 | 0.69 | TSHR (0.41) | TSHRPOLBRAB9ATHRBSMN1; SMN2 | |
| SCHEMBL12858249 | 0.69 | RAB9A (0.53) | TSHRHSD17B10POLBRAB9ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | TSHR 4310/4885HSD17B10 3376/4885POLB 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.